RUSSIA’S MRNA CANCER VACCINE ENTEROMIX: PIONEERING A NEW PATH IN CANCER TREATMENT

Syed Akif Uddin; Humera Naz; Syeda Tayyaba Asif; Madiha Jamshed; Maria Khan; Hira Akther

doi:10.71146/kjmr619

Authors

Syed Akif Uddin Faculty of Pharmacy, Department of Pharmaceutics, Nazeer Hussain University, Karachi, Pakistan. Author
Humera Naz Faculty of Pharmacy, Department of Pharmaceutics, Federal Urdu University of Arts, Science and Technology, Karachi, Pakistan Author
Syeda Tayyaba Asif Department of Pharmacognosy, Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi, Pakistan Author
Madiha Jamshed Department of Pharmacognosy, Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi, Pakistan Author
Maria Khan Department of Pharmacognosy, Faculty of Pharmacy, Iqra University Author
Hira Akther Faculty of Pharmacy, Department of Pharmaceutics, Nazeer Hussain University, Karachi, Pakistan Author

DOI:

https://doi.org/10.71146/kjmr619

Keywords:

EnteroMix, cancer vaccine, mRNA immunotherapy, personalized medicine, Russia

Abstract

Recent breakthroughs in molecular immunology have accelerated the development of therapeutic cancer vaccines. In September 2025, the Russian Federal Medical and Biological Agency (FMBA) declared that its mRNA-based vaccine, EnteroMix, has successfully concluded over three years of preclinical testing and is now poised for clinical application. The vaccine has shown significant tumor suppression, a promising safety profile, and potential for individualized treatment. This review outlines the scientific foundation, methodology, preclinical data, early clinical findings, and the prospective impact of EnteroMix. Despite encouraging results, robust peer-reviewed studies, multicenter clinical trials, and long-term evaluations are critical before global adoption.